JPMorgan Reiterates Overweight Rating on Acadia Pharmaceuticals (ACAD)

Raymond James on Acadia Pharmaceuticals (ACAD): 'Negative Lean Evident After Closer Review'

Raymond James analyst Danielle Brill reiterated a Market Perform rating and {REMOVEPT} price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst comments "While it does appear that the panels input will contribute significantly to the FDAs decision (more so than other... More

Mizuho Securities on Acadia Pharmaceuticals (ACAD): 'Adequacy and Reliability of Data are Key Risks to Upcoming AdComm'

Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)

The analyst comments "This morning, the FDA released the briefing document for pimavanserin in the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis... More

RBC Capital Reiterates Outperform Rating on Acadia Pharmaceuticals (ACAD)

RBC Capital analyst Gregory Renza reiterated an Outperform rating and $32.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)

The analyst comments "FDA briefing documents were released this morning ahead of Fridays FDA Psychopharmacologic Drugs AdComm Meeting for a refiled sNDA for pimavanserin in ADP,... More

Needham & Company Stays Sidelined on Acadia Pharmaceuticals (ACAD), 'No Major Surprises in AdCom Docs; FDA Concerns Stand'

Needham & Company analyst Ami Fadia reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst comments "FDA released briefing documents for the upcoming Adcom for Acadia's application for pimavanserin in Alzheimer's disease Psychosis (ADP). There are no major surprises in the document... More

Morgan Stanley on Acadia Pharmaceuticals (ACAD): 'we believe risk/reward remains skewed to the upside'

Morgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $24.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst comments "Overall, the FDA's commentary was skeptical,as expected, with regards to the efficacy data supporting approval in ADP. However, we believe that the... More

"Confused By Stock Reaction, Do Not View Documents as Supportive" - Stifel Weighs in Acadia Pharma (ACAD) Stock Soars

Shares of Acadia Pharma (NASDAQ: ACAD) are seeing heavy action Wednesday morning - up over 11% - after the publication of FDA briefing documents on the company's pimavanserin ADP submission.

Commenting on the news, Stifel analyst Paul Matteis notes that the published documents "align with... More

Stifel on Acadia Pharmaceuticals (ACAD): 'We're Confused By Stock Reaction'

Stifel analyst Paul Matteis reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD).

The analyst comments "FDA briefing documents on the pimavanserin ADP submission align with our expectations. FDA is critical of the ph2 ADP results for pimavanserin, bringing up all the bear cases:... More

Acadia Pharma (ACAD): Stifel Confused By Stock Reaction

Stifel analyst Paul Matteis says confused by stock reaction in Acadia Pharma (NASDAQ: ACAD) following FDA briefing docs.

The analyst commented, "FDA briefing documents on the pimavanserin ADP submission align with our expectations. FDA is critical of the ph2 ADP results for... More

Acadia Pharma (ACAD) Gains Following Posting of Briefing Documents for PIMAVANSERIN

(Updated - June 15, 2022 8:52 AM EDT)

(Updated - June 15, 2022 8:50 AM EDT)

Acadia Pharma (NASDAQ: ACAD) climbed pre-market after the FDA posted briefing documents for PIMAVANSERIN for treatment of hallucinations and delusions associated with Alzheimer's Disease.

Shares were up 40%.